Indeed, more than 10 different clinical trials investigating STAT3 inhibitors in various solid tumors, hematologic neoplasms, or psoriasis are currently ongoing or have already been completed (www.clinicaltrials.gov), highlighting that STAT3 is considered as a prime target for pharmaceutical intervention. Here, STAT3 is linked to hematopoietic and lymphoid system neoplasm.